 Verrica Pharmaceuticals NASDAQ:VRCA shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum. Verrica Pharmaceuticals stock has been falling Tuesday, down 16.37 to a price of 10.06. 